Wordt geladen...
Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. It is often associated with activating mutations in KRAS leading to deregulation of major signaling pathways as the RAS-RAF-MAPK and PI3K-Akt. However, the therapeutic options for CRC patients harboring somatic KRAS mutations...
Bewaard in:
| Gepubliceerd in: | Oncotarget |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Impact Journals LLC
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5356572/ https://ncbi.nlm.nih.gov/pubmed/27602501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11843 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|